Align Technology, Inc. · ALGN · FY2024 Q3 · Calendar Q4 2024

Align Technology: International Growth Offsets U.S. Weakness

The supplied analysis points to a mixed quarter: international clear-aligner demand and Systems & Services growth supported the business, while U.S. weakness, pricing pressure, and restructuring-related costs limited the near-term picture. The longer-term case depends on successful product adoption and execution.

Reported After market closeNASDAQHealthcare $10.98B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $2.35 Consensus $2.31
EPS surprise +1.7% Reported versus consensus
Reported revenue $977.9M Consensus $1.00B
Revenue surprise -2.5% Reported versus consensus

Market reaction

event-close to next-session close
Stock move +4.2% Event window
SPY move +0.2% Same window
Abnormal move +4.0% Stock minus SPY
Volume 2.6× Versus trailing sessions
Subsequent drift +5.4% Up to 20 sessions
ALGNSPY benchmark

Ask FN2 about ALGN FY2024 Q3

Transcript, numbers and history already loaded
Why did ALGN rise 4.2% after beating EPS estimates in FY2024 Q3?What changed in ALGN's guidance and outlook in FY2024 Q3?Give me the bull and bear case for ALGN after FY2024 Q3 earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

The current analysis shifts emphasis toward strong Systems & Services growth, record teen case starts, and new product availability, while U.S. demand remained weak. It also highlights restructuring, direct 3D-printing investment, and a maintained outlook with lower near-term GAAP margin from restructuring charges.

Guidance delta

Guidance sentiment was maintained. The supplied analysis says Q4 revenue was expected at $995–$1,015 million, with slightly lower GAAP margin because of restructuring charges.

Key takeaways

  • Systems & Services growth and international clear-aligner demand were the main positives.
  • U.S. weakness, pricing pressure, and restructuring costs remained the key offsets.
  • New products and digital workflows expand the platform, but adoption and execution remain important.

Management priorities

  • Expand iTero Lumina and related software capabilities.
  • Scale direct 3D-printed appliances and broaden the Palatal Expander rollout.
  • Invest in digital workflow tools, international expansion, and DSO relationships.
  • Pursue the restructuring and cost actions described in the supplied analysis.

Follow ALGN with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
ALGN EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 3 future estimate-only quarters. Q4 '23 estimate $2.18 Q4 '23 actual $2.42, beat Q1 '24 estimate $1.97 Q1 '24 actual $2.14, beat Q2 '24 estimate $2.34 Q2 '24 actual $2.41, beat Q3 '24 estimate $2.31 Q3 '24 actual $2.35, beat Q2 '25 estimate $2.57 Q2 '25 actual $2.49, miss Q3 '25 estimate $2.40 Q3 '25 actual $2.61, beat Q4 '25 estimate $2.99 Q4 '25 actual $3.29, beat Q1 '26 estimate $2.30 Q1 '26 actual $2.58, beat Q2 '26 estimate $2.62 Q2 '26 actual $2.64, beat Q3 '26 estimate $2.77 Q4 '26 estimate $3.27 Q1 '27 estimate $2.69
Show less

Analyst Consensus ?

ConsensusBuy33 ratings
Bullish2266.7%
Neutral927.3%
Bearish26.0%

Analyst 52W Price Targets

$154.51Current
$140Low
$284.72Average
$790High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 25, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Mizuho Outperform OutperformMaintainOct 22, 2026
Piper Sandler Overweight OverweightMaintainOct 21, 2026
Baird Neutral OutperformDowngradeOct 15, 2026
Leerink Partners Outperform OutperformMaintainOct 14, 2026
Stifel Buy BuyMaintainOct 9, 2026
Show 28 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $154.51. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Piper SandlerAnalyst unavailable$205$150.5 +32.7%Oct 21, 2026
Robert W. BairdAnalyst unavailable$162$144.44 +4.8%Oct 15, 2026
Leerink PartnersAnalyst unavailable$215$143.14 +39.1%Oct 14, 2026
Stifel NicolausJonathan Block$175$141.03 +13.3%Oct 9, 2026
UBSAnalyst unavailable$189$166.86 +22.3%Jul 23, 2026
See 47 more

Track every rating change on ALGN the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Align Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry. The company's operations are divided into two main business units: "Clear Aligner" and "Scanners and Services." The Clear Aligner segment offers a variety of solutions. Its comprehensive products include the full Invisalign treatment for teenage patients, designed to address complex orthodontic needs such as mandibular advancement, patient compliance tracking, and managing tooth eruption. It also features specialized Invisalign First Phase I and Phase 2 packages for younger children, typically aged seven to ten, who have mixed dentition (a combination of primary and permanent teeth).…

Historical context

All ALGN earnings
-3.7%FY2026 Q2 · Calendar Q3 2026-1.3%FY2026 Q1 · Calendar Q2 2026+4.9%FY2025 Q3 · Calendar Q4 2025

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
RDY Dr. Reddy's Laboratories Limited FY2027 Q2 · Calendar Q4 2026 +24.0% -0.2% Dr. Reddy’s: margins improve as semaglutide rollout advances
DGX Quest Diagnostics Incorporated FY2026 Q3 · Calendar Q4 2026 +4.5% +1.8% Quest Diagnostics: growth broadens, but PAMA remains a headwind
ARGX argenx SE FY2026 Q3 · Calendar Q4 2026 — -1.6% argenx: VYVGART momentum and a broader late-stage pipeline
MEDP Medpace Holdings, Inc. FY2026 Q3 · Calendar Q4 2026 +9.0% -1.3% Medpace: Record awards lift backlog as 2026 outlook improves
MOH Molina Healthcare, Inc. FY2026 Q3 · Calendar Q4 2026 +12.7% +0.8% Molina reaffirms 2026 outlook as Florida contract scales

Latest beats and misses

Who reports next

Beat on EPS

Missed on EPS

Get the ALGN recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
  3. Polygon adjusted daily market bars · 2026-10-25T06:40:42.342228+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-25T06:40:42.338842+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-25. For educational purposes only; not investment advice.